Product Description: AT9283 is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, JAK2/3, Abl (T315I) and Flt3 (IC50s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo[1][2].
Applications: Cancer-Kinase/protease
Formula: C19H23N7O2
Citations: Cancers (Basel). 2022 Mar 19;14(6):1575./Harvard Medical School LINCS LIBRARY/J Adv Res. 2023 Mar 7;S2090-1232(23)00070-X./Patent. US20180263995A1./Sci Transl Med. 2018 Jul 18;10(450):eaaq1093./Front Oncol. 2021 Jun 18;11:656608./PLoS Pathog. 2022 Jun 13;18(6):e1010620.
References: [1]Howard S, et al. Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity. Journal of Medicinal Chemistry (2009), 52(2), 379-388./[2]Qi W, et al. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas. Int J Cancer. 2012 Jun 15;130(12):2997-3005./[3]Santo L, et al. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin Cancer Res. 2011 May 15;17(10):3259-71
CAS Number: 896466-04-9
Molecular Weight: 381.43
Compound Purity: 99.70
Research Area: Cancer
Solubility: DMSO : ≥ 100 mg/mL
Target: Apoptosis;Aurora Kinase;Autophagy;Bcr-Abl;FLT3;JAK
English
Deutsch
